Insider Transactions in Q4 2020 at Exelixis, Inc. (EXEL)
Insider Transaction List (Q4 2020)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 28
2020
|
Michael Morrissey President and CEO |
SELL
Bona fide gift
|
Indirect |
126,565
-11.31%
|
-
|
|
Dec 18
2020
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Open market or private sale
|
Direct |
65,000
-18.67%
|
$1,300,000
$20.01 P/Share
|
|
Dec 18
2020
|
Peter Lamb EVP, Scientific Strategy & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
65,000
+15.73%
|
$65,000
$1.7 P/Share
|
|
Dec 17
2020
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Bona fide gift
|
Direct |
2,500
-0.51%
|
-
|
|
Dec 04
2020
|
Lance Willsey Director |
BUY
Exercise of conversion of derivative security
|
Direct |
106,142
+18.28%
|
$530,710
$5.82 P/Share
|
|
Nov 24
2020
|
Vincent T Marchesi Director |
SELL
Open market or private sale
|
Direct |
40,004
-30.72%
|
$720,072
$18.5 P/Share
|
|
Nov 24
2020
|
Vincent T Marchesi Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,004
+23.5%
|
$200,020
$5.82 P/Share
|
|
Nov 20
2020
|
Michael Morrissey President and CEO |
BUY
Bona fide gift
|
Indirect |
187,239
+14.34%
|
-
|
|
Nov 20
2020
|
Michael Morrissey President and CEO |
SELL
Bona fide gift
|
Direct |
187,239
-32.63%
|
-
|
|
Nov 15
2020
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
14,953
-1.02%
|
$299,060
$20.16 P/Share
|
|
Nov 15
2020
|
Jeffrey Hessekiel EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+5.72%
|
$210,000
$7.27 P/Share
|
|
Nov 15
2020
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
10,261
-0.72%
|
$205,220
$20.16 P/Share
|
|
Nov 15
2020
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,311
-1.29%
|
$226,220
$20.16 P/Share
|
|
Nov 15
2020
|
Christopher J. Senner EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
13,597
-1.77%
|
$271,940
$20.16 P/Share
|
|
Nov 15
2020
|
Patrick J. Haley EVP, Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
10,446
-1.41%
|
$208,920
$20.16 P/Share
|
|
Nov 15
2020
|
Michael Morrissey President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
24,954
-1.41%
|
$499,080
$20.16 P/Share
|
|
Nov 10
2020
|
Jack L Wyszomierski Director |
SELL
Open market or private sale
|
Direct |
34,000
-14.67%
|
$680,000
$20.61 P/Share
|
|
Nov 10
2020
|
Jack L Wyszomierski Director |
BUY
Exercise of conversion of derivative security
|
Direct |
62,403
+21.21%
|
$312,015
$5.82 P/Share
|
|
Oct 22
2020
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
53,022
-15.26%
|
$1,113,462
$21.79 P/Share
|
|
Oct 22
2020
|
Peter Lamb EVP, Scientific Strategy & CSO |
BUY
Grant, award, or other acquisition
|
Direct |
213,879
+38.1%
|
-
|
|
Oct 22
2020
|
Christopher J. Senner EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
46,920
-15.33%
|
$985,320
$21.79 P/Share
|
|
Oct 22
2020
|
Christopher J. Senner EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
178,231
+36.8%
|
-
|
|
Oct 22
2020
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
46,742
-8.97%
|
$981,582
$21.79 P/Share
|
|
Oct 22
2020
|
Jeffrey Hessekiel EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
178,231
+25.48%
|
-
|
|
Oct 22
2020
|
Patrick J. Haley EVP, Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
44,184
-15.04%
|
$927,864
$21.79 P/Share
|
|
Oct 22
2020
|
Patrick J. Haley EVP, Commercial |
BUY
Grant, award, or other acquisition
|
Direct |
178,231
+37.76%
|
-
|
|
Oct 22
2020
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
55,235
-10.1%
|
$1,159,935
$21.79 P/Share
|
|
Oct 22
2020
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
BUY
Grant, award, or other acquisition
|
Direct |
213,879
+28.11%
|
-
|
|
Oct 22
2020
|
Michael Morrissey President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
177,132
-22.83%
|
$3,719,772
$21.79 P/Share
|
|
Oct 22
2020
|
Michael Morrissey President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
672,861
+46.44%
|
-
|
|
Oct 21
2020
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
39,742
-10.38%
|
$834,582
$21.95 P/Share
|
|
Oct 21
2020
|
Jeffrey Hessekiel EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
39,742
+9.41%
|
$278,194
$7.27 P/Share
|
|
Oct 08
2020
|
Christopher J. Senner EVP and CFO |
SELL
Open market or private sale
|
Direct |
10,000
-7.25%
|
$250,000
$25.0 P/Share
|
|
Oct 08
2020
|
Christopher J. Senner EVP and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+6.76%
|
$30,000
$3.66 P/Share
|